TORONTO – Some of the most active companies traded Monday on the Toronto Stock Exchange:
Toronto Stock Exchange (14,337.77, up 110.09 points):
Niko Resources Ltd. (TSX:NKO). Oil and gas. Down 40 cents, or 54.79 per cent, to 33 cents on 10.5 million.
Pacific Rubiales Energy Corp. (TSX:PRE). Oil and gas. Up $1.79, or 11.24 per cent, to $17.72 on 5.3 million shares.
Southern Pacific Resource Corp. (TSX:STP). Oil and gas. Unchanged at 2.5 cents on 4.5 million shares.
BlackBerry Limited (TSX:BB). Communication equipment. Up 93 cents, or 8.69 per cent, to $11.63 on 4.2 million shares.
Canadian Natural Resources Ltd. (TSX:CNQ). Oil and gas. Down 39 cents, or 1.01 per cent, to $38.26 on 3.8 million shares.
Uranium Participation Corp. (TSX:U). Miner. Down five cents, or one per cent, to $4.96 on 3.7 million shares.
Companies reporting major news:
Canadian Pacific Railway Ltd. (TSX:CP). Transportation. Down $3.34, or 1.48 per cent, to $221.65 on 437,637 shares. The company confirmed that talks with U.S. peer CSX Corp. have ended without a deal, putting a damper on the Calgary-based company’s hopes for an expanded North American rail network.
Mitel Networks Corp. (TSX:MNW). Communication equipment. Down 32 cents, or 3.37 per cent, to $9.18 on 44,919 shares. The Ottawa-based communications equipment maker says it has offered to buy ShoreTel Inc. for about $540 million in cash but the proposal has been rejected by the California-based company’s board. The company says it remains open to further discussions with ShoreTel and will leave the offer on the table until Nov. 20.
Rogers Communications (TSX:RCI.B). Communication services. Up $1.39, or 3.29 per cent, to $43.67 on 1.1 million shares. Rogers announced it was teaming with Netflix to deliver the original survivalist thriller series “Between.” It is Netflix’s first partnership with a Canadian broadcaster.
Valeant Pharmaceuticals International Inc. (TSX:VRX). Drug, health products manufacturer. Up $5.30, or 3.91 per cent, to $140.74 on 399,848 shares. The company reported its second-best ever quarterly results and a higher growth forecast, adding that it is considering raising its hostile takeover bid for Botox maker Allergan Inc.